Ebola triples, response misfires

The first confirmed Bundibugyo Ebola case appeared in South Kivu Province on 21 May 2026, a territory under M23 rebel control since February 2025. The 28-year-old patient died before diagnosis was confirmed. Residents torched a treatment facility on the response team's arrival.

South Kivu has no outbreak-management apparatus under M23 governance. The case follows from Ituri's low contact-tracing coverage (21%), which left transmission chains undetected long enough to cross provincial borders into ungoverned territory . Read full version ↓

The United States imposed a three-week entry ban on nationals of DRC, Uganda and South Sudan on 18 May 2026, including green-card holders. South Sudan had no confirmed Bundibugyo cases. Africa CDC publicly opposed the restriction on 19 May. The IHR Emergency Committee's 22 May Temporary Recommendations explicitly advised against travel or trade restrictions.

The ban runs counter to standard outbreak-response doctrine and directly contradicts IHR guidance. Its inclusion of South Sudan, which has no confirmed cases, suggests a political-risk logic distinct from the epidemiological evidence. The US no longer has a deployable field surge capacity to offer as an alternative. Read full version ↓

Dr Peter Stafford, a 39-year-old American surgeon working with the missionary group Serge in Bunia, was confirmed with Bundibugyo Ebola on 20 May 2026 and evacuated to Germany. He had been operating in Bunia from around 11 May, during the outbreak's undetected phase. Germany placed Stafford's wife and four children under three-week symptom monitoring.

Stafford is the first US citizen confirmed with Bundibugyo Ebola. His nine-day exposure window, operating without species-confirmed protocols, illustrates how the pre-PHEIC detection gap put medical staff at risk before any outbreak-specific guidance reached the field. Read full version ↓

The IHR Emergency Committee, the expert panel the WHO director-general normally consults before declaring a global health emergency, met on 19 May 2026 after Tedros had already declared the PHEIC on 17 May . Its Temporary Recommendations, issued 22 May, call for border exit screening, 21-day contact tracing, and safe burials. The committee explicitly advised against travel or trade restrictions.

The committee confirmed the PHEIC but did not raise it to the new Pandemic Emergency tier. Its travel-restriction guidance directly contradicts the US entry ban imposed four days earlier on nationals from DRC, Uganda and South Sudan. Read full version ↓

The 79th World Health Assembly deferred adoption of the PABS annex to the Pandemic Agreement on 19 May 2026, extending negotiations to WHA80 in May 2027 or a special session. A seventh round of talks is scheduled for 6 to 17 July 2026. Without the PABS annex, the Pandemic Agreement cannot be ratified.

PABS is the mechanism meant to ensure countries that share pathogen samples get fair access to vaccines made from them. The stalemate continues the dispute over viral sovereignty that Indonesia first raised in 2007 over H5N1 samples, and that the 2009 H1N1 pandemic exposed as unresolved at the cost of equitable vaccine access. Read full version ↓

A WHO-sponsored trial of remdesivir and MBP134, a monoclonal antibody cocktail showing 100% animal protection against Bundibugyo Ebola up to eight days post-infection, is ready to begin but requires regulatory sign-off from DRC and Uganda. No dosing has started as of 20 May 2026.

About 2,000 doses of Ervebo, a vaccine licensed for Zaire ebolavirus only, sit in DRC stockpiles. Both countries' regulatory frameworks lack the expedited compassionate-use pathways that allowed ZMapp to reach patients within days during the 2014 outbreak . Oxford's ChAdOx-platform Bundibugyo vaccine candidate needs two to three more months before it can begin trial dosing; an rVSV-platform candidate is six to nine months out. Read full version ↓

The 79th World Health Assembly adopted the Global Action Plan on antimicrobial resistance 2026-2036 on 23 May 2026, targeting a 10% cut in bacterial AMR deaths by 2030 under a One Health framework. Bacterial AMR was associated with 4.71 million deaths in 2021 and is projected to cause 39 million deaths a year by 2050.

This is the most substantive multilateral AMR commitment since the 2015 Global Action Plan and the 2016 UN General Assembly High-Level Meeting, neither of which produced binding national legislation. The 2026 plan shares their non-binding architecture. Africa CDC's ARILAC network, launched 6 May to build AMR laboratory capacity across eight African states , represents the more operationally concrete parallel initiative. Read full version ↓

WHO Disease Outbreak News 595, published 20 May 2026, reported a recombinant mpox virus carrying genetic material from both clade Ib and clade IIb. The variant was first found in a UK traveller in December 2025 and identified retrospectively in India from September 2025. It now spans at least four countries across three WHO regions.

WHO called it premature to draw conclusions about transmissibility and reported no serious complications in identified patients. This is a surveillance watch item: the recombinant's eight months of apparent quiet circulation without an outbreak signal suggests it has not gained the transmission or virulence properties that would make it a near-term PHEIC candidate. Read full version ↓

The MV Hondius Andes hantavirus cluster reached 12 cases and three deaths as of 24 May 2026, with passengers traced to 12 countries. The ship docked at Rotterdam on 18 May. ECDC confirmed only one new case since 12 May, suggesting the cluster is stabilising.

Andes virus is the only hantavirus capable of person-to-person transmission. The slow case accrual since the 12 May ECDC update indicates primary exposure on the ship is not generating substantial secondary chains, though the monitoring window for close contacts extends through early June. Read full version ↓

CEPI committed $54.3 million in May 2026 to continue Moderna's Phase 3 mRNA-1018 H5N1 vaccine trial after the US Department of Health and Human Services pulled federal funding. First participants were dosed on 21 April 2026. This is the furthest any mRNA H5N1 vaccine candidate has advanced.

The CEPI rescue matters because H5N1 is expanding in US dairy cattle and widening its mammalian host range. If the trial completes, it provides a validated mRNA platform that could be adapted rapidly for a pandemic strain. The HHS funding withdrawal makes CEPI the single funder of record for the most advanced H5N1 mRNA defence currently active . Read full version ↓